Şizofrenide Lurasidon ve Brekspiprazol Kullanımı: Güncel Klinik Yaklaşımlar

Liu N, Xu L, Guan X, et al. Brain functional connectivity associated with cognitive deficits in younger patients at first episode of schizophrenia. Schizophrenia Research: Cognition. 2025;41:100359. doi: 10.1016/j.scog.2025.100359.

Dyu T, Leung C, Simões-e-Silva AC. Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study. Human Vaccines and Immunotherapeutics.2024;20(1):2379865. doi: 10.1080/21645515.2024.2379865.

Ngubane NP, Mabandla M V, De Gama BZ. The antipsychotic potential of Salix Mucronata on ketamine-induced rats. IBRO Neuroscience Reports. 2024;17:96-107. doi:10.1016/j.ibneur.2024.06.003.

Ayık B, Erdoğan A. Çocuk ve Ergenlerde Görülen Psikotik Bozuklukların Tedavisinde Kullanılan Atipik Antipsikotikler. Turkiye Klinikleri Child Psychiatry. 2015;1(3):39-53.

Lim DXE, Yeo SY, Chia ZYA, et al. Schizophrenia: Genetics, neurological mechanisms, and therapeutic approaches. Neural Regeneration Research. 2026;21(3):1089–1103. doi: 10.4103/NRR.NRR-D-24-01375.

Inoue T, Masuda T, Sano F, et al. Lurasidone for bipolar I depression with comorbid anxiety symptoms: Post-hoc-analysis of randomized, placebo-controlled studies. Journal of Affective Disorders. 2025;385:119348. doi: 10.1016/j.jad.2025.05.008.

Atkinson SD, Shah A, Burgess MV, et al. Safety and Tolerability of Brexpiprazole in Adolescents With Schizophrenia: A Long-Term, Open-Label Study. Journal of the American Academy of Child and Adolescent Psychiatry Open. 2024;3(2):313-322. doi: 10.1016/j.jaacop.2024.04.005.

Li C, Yang L, Zhang Q, et al. Characterization of the Molecular Mechanisms Underlying Lurasidone‐Induced Acute Manic Episodes in Bipolar Depression: A Network Pharmacology and Molecular Docking Approach. CNS Neuroscience and Therapeutics. 2025;31(4):e70383. doi: 10.1111/cns.70383.

Citrome L, Álvarez-Barón E, Gabarda-Inat I, et al. The specific anti-hostility effect of lurasidone in patients with an acute exacerbation of schizophrenia: results of pooled post hoc analyses in adolescents and adults. International Clinical Psychopharmacology. 2024;40(4):214-223. doi: 10.1097/YIC.0000000000000563.

Felemban RA, Abduljabbar MH, Alnemari RM, et al. Box–Behnken optimized MPA-CdTe quantum dots as turn-off fluorescent probes for sensitive lurasidone determination in pharmaceutical, biological, and environmental matrices. RSC Advances. 2025;15(12):8855-8866. doi: 10.1039/d5ra00519a.

Bernardo M, Marsá MD, González-Pinto A, et al. Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel. Neurology and Therapy. 2025;14(1):85-98. doi: 10.1007/s40120-024-00700-y.

Kamińska Z, Basa A, Pyzel Ł, et al. Development studies on the orodispersible freeze-dried platforms for lurasidone hydrochloride − Understanding the effect of amino acid additive and lyophilization stage. International Journal of Pharmaceutics. 2025;670:125122. doi: 10.1016/j.ijpharm.2024.125122.

Kowalczyk E, Koziej S, Soroka E. Advances in Mood Disorder Pharmacotherapy: Evaluating New Antipsychotics and Mood Stabilizers for Bipolar Disorder and Schizophrenia. Medical Science Monitor. 2024;30:e945412. doi: 10.12659/MSM.945412.

Sözer G, Nacak M, Durucu E, et al. Bioequivalence study of two formulations of lurasidone film coated tablets in healthy subjects under fed conditions. Scientific Reports. 2025;15(1):20492. doi: 10.1038/s41598-025-04800-z.

Song T, Wang W, Wu Y, et al. Functional Liposomes Improve the Oral Absorption of Lurasidone Hydrochloride by Overcoming Multiple Absorption Barriers and Eliminating Food Effect. International Journal of Nanomedicine. 2025;20:4883-4901. doi: 10.2147/IJN.S512876.

Ismail Z, Meehan SR, Farovik A, et al. Effects of brexpiprazole on patient life engagement in schizophrenia: post hoc analysis of Positive and Negative Syndrome Scale data. Current Medical Research and Opinion. 2025;145–153. doi: 10.1080/03007995.2024.2440059.

Lee KY, Choo SY, Tang CT. Neuroleptic Malignant Syndrome Following Brexpiprazole Initiation in a Treatment-Resistant Schizophrenia Patient With Influenza A: A Case Report. Cureus. 2025;17(4):e83087. doi: 10.7759/cureus.83087.

Ahmad SR, Zeyaullah M, AlShahrani AM, et al. Unlocking the potential of lumateperone and novel anti-psychotics for schizophrenia. Bioimpacts. 2024;30259. doi: 10.34172/bi.30259.

Mucci F, Arone A, Gurrieri R, et al. Third-Generation Antipsychotics: The Quest for the Key to Neurotrophism. Life. 2025;15(3):391. doi: 10.3390/life15030391.

Carreras MTG, Suárez LJ, García LL, et al. Towards full recovery with lurasidone: effective doses in the treatment of agitation, affective, positive, and cognitive symptoms in schizophrenia and of dual psychosis. Drugs Context. 2024;2024-4–4. doi: 10.7573/dic.2024-4-4.

Siwek M, Chrobak AA, Gorostowicz A, et al. Lurasidone Augmentation of Clozapine in Schizophrenia—Retrospective Chart Review. Brain Sciences. 2023;13(3):445. doi: 10.3390/brainsci13030445.

Maruyama H, Sano F, Sakaguchi R, et al. Effect of Lurasidone on Life Engagement in Schizophrenia: Post-Hoc Analysis of the JEWEL Study. Neuropsychiatric Disease and Treatment. 2024;1453-1463. doi: 10.2147/NDT.S466479.

Kim SH, Jung DU, Kim DH, et al. Efficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial. Psychiatry Investigation. 2024;21(7):762-771. doi: 10.30773/pi.2024.0052.

Yoshikawa A, Li J, Alliey-Rodriguez N, et al. Genetic markers of early response to lurasidone in acute schizophrenia. Pharmacogenomics Journal. 2025;25(1):3. doi: 10.1038/s41397-024-00360-z.

Derayea SM, Zaafan AAS, Nagy DM, et al. Development and validation of a precise flow injection method for the assessment of brexpiprazole, with application to pharmaceutical dosage forms and human plasma analysis. BMC Chemistry. 2024;18(1):137. doi: 10.1186/s13065-024-01240-0.

Siwek M, Wojtasik-Bakalarz K, Krupa AJ, et al. Brexpiprazole—Pharmacologic Properties and Use in Schizophrenia and Mood Disorders. Brain Sciences. 2023;13(3):397. doi: 10.3390/brainsci13030397.

Mohr P, Masopust J, Kopeček M. Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy? Frontiers in Psychiatry. 2022;781946. doi: 10.3389/fpsyt.2021.781946.

Guilera T, Pascual JPC, del Carmen Blasco M, et al. Lurasidone for the treatment of schizophrenia in adult and paediatric populations. Drugs Context. 2023;2022-10–1. doi: 10.7573/dic.2022-10-1.

Mielczarek Z, Trędzbor B, Piekarska-Bugiel K, et al. Neutropenia in a schizophrenia patient following combined lurasidone and paliperidone therapy: a case report. Advances in Psychiatry and Neurology. 2023;152-155. doi: 10.5114/ppn.2023.132474.

Živković N, Mrkalić E, Jelić R, et al. The Molecular Recognition of Lurasidone by Human Serum Albumin: A Combined Experimental and Computational Approach. Molecules. 2025;30(7):1420. doi: 10.3390/molecules30071420.

Cavallotto C, Chiappini S, Mosca A, et al. Examining Lurasidone Efficacy in Patients with Schizophrenia Spectrum Illness and Concurrent Alcohol and Substance Use Disorder: A Prospective, Multicentric, Real-World Investigation. Journal of Clinical Medicine. 2024;13(8):2206. doi: 10.3390/jcm13082206.

Miura I, Horikoshi S, Ichinose M, et al. Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy. Drug Design, Development and Therapy. 2023;3023-3031. doi: 10.2147/DDDT.S366769.

Bieńkow ki P, Wichniak A, Klinika Psychiatryczna K, et al. Efficacy and tolerability of brexpiprazole – a new antipsychotic drug from the group of dopamine D2 receptor partial agonists. Psychiatria Polska. 2024;237–248. doi: 10.12740/PP/OnlineFirst/169646.

Brubaker M, Kapadia S, Maletic V, et al. Preclinical Evidence for the Use of Brexpiprazole + Antidepressant Treatment for Major Depressive Disorder and Post-Traumatic Stress Disorder: A Systematic Review. Neuropsychiatric Disease and Treatment . 2025;21:421-436. doi: 10.2147/NDT.S501207.

Orzelska-Górka J, Mikulska J, Wiszniewska A, et al. New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. International Journal of Molecular Sciences. 2022;10624. doi: 10.3390/ijms231810624.

Zhao M, Qin B, Mao Y, et al. Efficacy and Safety of Low-Dose Brexpiprazole for Acute Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials. Neuropsychiatric Disease and Treatment. 2022;1705-1713. doi: 10.2147/NDT.S374577.

Fukuyama K, Motomura E, Okada M. Brexpiprazole Reduces 5-HT7 Receptor Function on Astroglial Transmission Systems. International Journal of Molecular Sciences. 2022;6571. doi: 10.3390/ijms23126571.

Fiorillo A, Sampogna G, Albert U, et al. The Role of Lurasidone in Managing Depressive Symptoms in People with Schizophrenia: A Review. Brain Sciences. 2024;14(3):225. doi: 10.3390/brainsci14030225.

Corridori E, Salviati S, Begni V, et al. Restorative properties of chronic lurasidone treatment on emotional dysfunction in rats exposed to chronic unavoidable stress: A role for medial prefrontal cortex - nucleus accumbens network. Neuropharmacology. 2025;267:110302. doi: 10.1016/j.neuropharm.2025.110302.

Nakagome K, Tachimori H, Endo S, et al. A multicenter, single‐arm, open‐label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder. Neuropsychopharmacology Reports. 2024;187-196. doi: 10.1002/npr2.12416.